These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 20144071)

  • 1. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.
    Schmieder RE
    Clin Exp Hypertens; 2010 Jan; 32(1):35-42. PubMed ID: 20144071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
    Bramlage P
    Expert Opin Pharmacother; 2009 Aug; 10(11):1755-67. PubMed ID: 19538001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine.
    Mourad JJ; Le Jeune S; Pirollo A; Mourad C; Gaudouen Y; Lopez-Sublet M
    Curr Med Res Opin; 2010 Sep; 26(9):2263-76. PubMed ID: 20690889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertension management: rationale for triple therapy based on mechanisms of action.
    Neutel JM; Smith DH
    Cardiovasc Ther; 2013 Oct; 31(5):251-8. PubMed ID: 23121769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME; Epstein BJ
    J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension.
    Waeber B
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):43-50. PubMed ID: 15030296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
    Neutel JM
    Curr Med Res Opin; 2008 Aug; 24(8):2389-401. PubMed ID: 18616863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypertension combination therapy with renin-angiotensin system blockers].
    Soucek M
    Vnitr Lek; 2009 Sep; 55(9):719-23. PubMed ID: 19785368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.
    Gojanovic B; Feihl F; Liaudet L; Waeber B
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):1-9. PubMed ID: 18404602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antihypertensive drugs: recommendations for use.
    Skolnik NS; Beck JD; Clark M
    Am Fam Physician; 2000 May; 61(10):3049-56. PubMed ID: 10839554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.
    Oparil S; Weber M
    Postgrad Med; 2009 Mar; 121(2):25-39. PubMed ID: 19332960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Lyle PA; Tershakovec AM; Devereux RB; Oparil S; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Wedel H
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):729-45. PubMed ID: 16262560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
    White WB
    Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.